Wells Fargo initiated coverage of Vera Therapeutics (VERA) with an Overweight rating and $70 price target The firm says atacicept “sets a high bar” for B-cell agents in IgA nephropathy and is poised to capture $2B-plus sales, in an area of growing interest. Wells likes the Vera setup into major 2025 catalysts and sees a large opportunity for atacicept in the $10B IgAN market.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VERA:
- Vera Therapeutics appoints Jason Carter as Chief Legal Officer
- Vera Therapeutics partners with University of Michigan on NEPTUNE match project
- Vera Therapeutics Advances in Autoimmune Treatment
- Vera Therapeutics reports Q3 EPS (85c), consensus (66c)
- Vera Therapeutics 7.14M share Secondary priced at $42.00
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
